These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35100271)

  • 1. A high-dose inoculum size results in persistent viral infection and arthritis in mice infected with chikungunya virus.
    Zhang Y; Yan H; Li X; Zhou D; Zhong M; Yang J; Zhao B; Fan X; Fan J; Shu J; Lu M; Jin X; Zhang E; Yan H
    PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010149. PubMed ID: 35100271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chikungunya Virus Evades Antiviral CD8
    Davenport BJ; Bullock C; McCarthy MK; Hawman DW; Murphy KM; Kedl RM; Diamond MS; Morrison TE
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32102875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
    Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
    Front Immunol; 2020; 11():304. PubMed ID: 32194557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
    Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
    Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response.
    Hawman DW; Stoermer KA; Montgomery SA; Pal P; Oko L; Diamond MS; Morrison TE
    J Virol; 2013 Dec; 87(24):13878-88. PubMed ID: 24131709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.
    Jones JE; Long KM; Whitmore AC; Sanders W; Thurlow LR; Brown JA; Morrison CR; Vincent H; Peck KM; Browning C; Moorman N; Lim JK; Heise MT
    mBio; 2017 Nov; 8(6):. PubMed ID: 29138302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.
    Morrison TE; Oko L; Montgomery SA; Whitmore AC; Lotstein AR; Gunn BM; Elmore SA; Heise MT
    Am J Pathol; 2011 Jan; 178(1):32-40. PubMed ID: 21224040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease.
    Broeckel RM; Haese N; Ando T; Dmitriev I; Kreklywich CN; Powers J; Denton M; Smith P; Morrison TE; Heise M; DeFilippis V; Messaoudi I; Curiel DT; Streblow DN
    Front Immunol; 2019; 10():2563. PubMed ID: 31736977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA.
    Young AR; Locke MC; Cook LE; Hiller BE; Zhang R; Hedberg ML; Monte KJ; Veis DJ; Diamond MS; Lenschow DJ
    PLoS Pathog; 2019 Aug; 15(8):e1007993. PubMed ID: 31465513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia.
    Huits R; De Kort J; Van Den Berg R; Chong L; Tsoumanis A; Eggermont K; Bartholomeeusen K; Ariën KK; Jacobs J; Van Esbroeck M; Bottieau E; Cnops L
    PLoS One; 2018; 13(4):e0196630. PubMed ID: 29709007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection.
    Poo YS; Rudd PA; Gardner J; Wilson JA; Larcher T; Colle MA; Le TT; Nakaya HI; Warrilow D; Allcock R; Bielefeldt-Ohmann H; Schroder WA; Khromykh AA; Lopez JA; Suhrbier A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3354. PubMed ID: 25474568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.
    Fox JM; Diamond MS
    J Immunol; 2016 Dec; 197(11):4210-4218. PubMed ID: 27864552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor plays a deleterious role in the pathogenesis of chikungunya virus infection.
    Moreira TP; Sousa CDF; Melo Costa VR; Queiroz-Junior CM; Santos FM; Bonilha CS; Ésper LM; Nogueira ML; Cunha TM; Teixeira MM; Costa VV; de Souza DDG
    Immunology; 2023 Mar; 168(3):444-458. PubMed ID: 36164989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology.
    Teo TH; Her Z; Tan JJ; Lum FM; Lee WW; Chan YH; Ong RY; Kam YW; Leparc-Goffart I; Gallian P; Rénia L; de Lamballerie X; Ng LF
    J Virol; 2015 Aug; 89(15):7955-69. PubMed ID: 25995257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).
    Dagley A; Ennis J; Turner JD; Rood KA; Van Wettere AJ; Gowen BB; Julander JG
    Antiviral Res; 2014 Aug; 108():1-9. PubMed ID: 24833276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection.
    Abdelnabi R; Jochmans D; Verbeken E; Neyts J; Delang L
    Antiviral Res; 2018 Jan; 149():113-117. PubMed ID: 28958920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.
    Kose N; Fox JM; Sapparapu G; Bombardi R; Tennekoon RN; de Silva AD; Elbashir SM; Theisen MA; Humphris-Narayanan E; Ciaramella G; Himansu S; Diamond MS; Crowe JE
    Sci Immunol; 2019 May; 4(35):. PubMed ID: 31101672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Persistence of Chikungunya Virus-Associated Manifestations and Anti-Chikungunya Virus Antibody in Southern Thailand: 5 Years After an Outbreak in 2008-2009.
    Ninla-Aesong P; Mitarnun W; Noipha K
    Viral Immunol; 2020 Mar; 33(2):86-93. PubMed ID: 31976828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.